This article is more than 5 years old. Information may no longer be current.
Prostate Cancer Foundation announces Challenge Awards
Click Here to Manage Email Alerts
The Prostate Cancer Foundation announced six new Challenge Awards funded in conjunction with the Movember Foundation.
The multiyear awards support crossdisciplinary teams of investigators who are involved in research designed to identify treatment advances and cures for prostate cancer.
The Movember Foundation donated $5.4 million to the Prostate Cancer Foundation to help fund this year’s Challenge Awards.
“The generous donation from the Movember Foundation enables teams of research scientists to accelerate the delivery of life-extending and life-saving therapies for men living with prostate cancer,” Jonathan W. Simons, MD, president and CEO of the Prostate Cancer Foundation, said in a press release. “As we embark upon the 10th year of our remarkable relationship with the Movember Foundation, we are grateful to continue our partnership as we continue to help further advance therapies and defeat prostate cancer once and for all.”
Challenge Award teams must include at least three investigators, one of whom must be a young investigator.
Six teams received $1 million awards. The projects and their team leaders are as follows:
- Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer — Felix Feng, MD, Alan Ashworth, PhD, and Charles Ryan, MD, all of University of California, San Francisco; Alexander Wyatt, PhD, of University of British Columbia; and other investigators from Memorial Sloan Kettering Cancer Center.
- Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody-Drug Conjugate — Joshua Lang, MD, of University of Wisconsin; Howard Scher, MD, of Memorial Sloan Kettering Cancer Center; Scott Dehm, PhD, of Masonic Cancer Center at University of Minnesota; and Scott Tagawa, MD, of Weill Cornell Medicine and New York-Presbyterian.
- Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer — Chad Mirkin, PhD, of Northwestern University.
- Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets — Ana Aparicio, MD, Nicholas Navin, PhD, and Theocharis Panaretakis, PhD, all of The University of Texas MD Anderson Cancer Center; and Peter Kuhn, PhD, of University of Southern California.
- Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer — Nupam Mahajan, PhD, of H. Lee Moffitt Cancer Center, and Felix Feng, MD, of University of California, San Francisco.
- Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer — Douglas McNeel, MD, PhD, of University of Wisconsin.